Last updated on September 2018

S0820 Adenoma and Second Primary Prevention Trial

Brief description of study

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon cancer.

Detailed Study Description

The purpose of this study is to assess whether eflornithine 500 mg or sulindac 150 mg are effective in reducing the 3-year event rate of high risk adenoma or second primary colorectal cancer in Stage 0, I II and III colon cancer patients. The primary hypothesis will test the main effect of each agent, as well as the comparison of placebo alone to the combination of sulindac and eflornithine.

Clinical Study Identifier: NCT01349881

Contact Investigators or Research Sites near you

Start Over

Patricia N. O'Kane, B.S.

East Bay Medical Oncology Hematology Medical Associates Inc-Pleasant Hill
Pleasant Hill, CA United States
  Connect »

Samantha A. Seaward

Kaiser Permanente-Walnut Creek
Walnut Creek, CA United States
  Connect »

James H. Feusner

Contra Costa Regional Medical Center
Martinez, CA United States
  Connect »